William A E Parker (William Ae Parker, William Parker)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 23

Top Topics

Anti Inflammatory Drugs

Acute Coronary Syndrome

Atrial Fibrillation

Antiplatelet Therapy

Top Venues

Cardiovascular diabetology

European heart journal

Cardiovascular drugs and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

William A E Parker, Robert F Storey
THE ROLE OF PLATELET P2Y 12 IN INFLAMMATION. British journal of pharmacology (2023)
Elizabeth E Gardiner, Gayle M Halford, William A E Parker
Platelets in 2023: hellos and goodbyes. Platelets 34 (1) (2023)
Elizabeth E Gardiner, Gayle M Halford, William A E Parker
Platelets in 2023: hellos and goodbyes. Platelets 34 (1) (2023)
Frances L Varian, William A E Parker, James Fotheringham, Robert F Storey
Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. Platelets 34 (1) (2022)
Elizabeth E Gardiner, Gayle M Halford, Paul Harrison, William A E Parker, Steve P Watson
Platelets and open access - a new era dawns. Platelets 33 (6) (2022)
William A E Parker, Robert F Storey
Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE? Cardiovascular research 117 (10) (2022)
William A E Parker, Rebecca Sagar, Zeyad Kurdee, Fladia Hawkins, Khalid M Naseem, Peter J Grant, Robert F Storey, Ramzi A Ajjan
A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. Cardiovascular diabetology 20 (1) (2021)
William A E Parker, Robert F Storey
Ticagrelor monotherapy in CKD: better safety at what price? European heart journal 42 (45) (2021)
Thomas A Nelson, William A E Parker, Tatevik Ghukasyan Lakic, Johan Westerbergh, Stefan K James, Agneta Siegbahn, Richard C Becker, Anders Himmelmann, Lars Wallentin, Robert F Storey
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets (2021)
William A E Parker, Robert F Storey
Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert opinion on emerging drugs 25 (1) (2020)
Aleksandra Gasecka, Josip Andjelo Borovac, Rui Azevedo Guerreiro, Michela Giustozzi, William A E Parker, Daniel Caldeira, Gemma Chiva-Blanch
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. Cardiovascular drugs and therapy 35 (2) (2020)
Barry W Hennigan, Richard Good, Carly Adamson, William A E Parker, Lynn Martin, Lynne Anderson, Michael Campbell, Patrick W Serruys, Robert F Storey, Keith G Oldroyd
Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. Platelets (2020)
William A E Parker, Robert F Storey
Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets 32 (1) (2020)
Bastiaan Zwart, William A E Parker, Robert F Storey
New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of clinical medicine 9 (7) (2020)
William A E Parker
Aspirin after PCI: in the twilight of its years? Platelets 31 (7) (2020)
William A E Parker, Robert F Storey
Antithrombotic therapy for patients with chronic coronary syndromes. Heart (British Cardiac Society) 107 (11) (2020)
William A E Parker, Christian Schulte, Temo Barwari, Fladia Phoenix, Sam M Pearson, Manuel Mayr, Peter J Grant, Robert F Storey, Ramzi A Ajjan
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular diabetology 19 (1) (2020)
Kok Weng Ow, William A E Parker, Mark M Porter, Jessica Hanson, Heather M Judge, Norman P Briffa, Mark R Thomas, Robert F Storey
Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets 31 (7) (2020)
Wael Sumaya, William A E Parker, Heather M Judge, Ian R Hall, Rachel C Orme, Zulfiquar Adam, James D Richardson, Alexander M K Rothman, Kenneth P Morgan, Julian P Gunn, Robert F Storey
Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets 32 (4) (2020)
William A E Parker, Diana A Gorog, Tobias Geisler, Gemma Vilahur, Dirk Sibbing, Bianca Rocca, Robert F Storey
Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European heart journal supplements : journal of the European Society of Cardiology 22 (Suppl M) (2020)
William A E Parker, Rachel C Orme, Jessica Hanson, Hannah M Stokes, Claire M Bridge, Patricia A Shaw, Wael Sumaya, Kirstie Thorneycroft, Giovanna Petrucci, Benedetta Porro, Heather M Judge, Ramzi A Ajjan, Bianca Rocca, Robert F Storey
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets 30 (2) (2019)
William A E Parker, Robert F Storey
Ticagrelor: agonising over its mechanisms of action. Blood 128 (23) (2018)
William A E Parker, Niclas Eriksson, Richard C Becker, Deepak Voora, Axel Åkerblom, Anders Himmelmann, Stefan K James, Lars Wallentin, Robert F Storey, null null
Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets 30 (5) (2018)